Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiang'an South Road, Xiamen, Fujian 361102, China.
Department of Orthopedics, The Fifth Hospital of Xiamen, Xiamen, Fujian 361101, China.
Theranostics. 2021 Jan 1;11(4):1732-1752. doi: 10.7150/thno.45302. eCollection 2021.
Estrogen and estrogen receptor (ER)-regulated gene transcriptional events have been well known to be involved in ER-positive breast carcinogenesis. Meanwhile, circular RNAs (circRNAs) are emerging as a new family of functional non-coding RNAs (ncRNAs) with implications in a variety of pathological processes, such as cancer. However, the estrogen-regulated circRNA program and the function of such program remain uncharacterized. CircRNA sequencing (circRNA-seq) was performed to identify circRNAs induced by estrogen, and cell proliferation, colony formation, wound healing, transwell and tumor xenograft experiments were applied to examine the function of estrogen-induced circRNA, circPGR. RNA sequencing (RNA-seq) and ceRNA network analysis wereperformed to identify circPGR's target genes and the microRNA (miRNA) bound to circPGR. Anti-sense oligonucleotide (ASO) was used to assess circPGR's effects on ER-positive breast cancer cell growth. Genome-wide circRNA profiling by circRNA sequencing (circRNA-seq) revealed that a large number of circRNAs were induced by estrogen, and further functional screening for the several circRNAs originated from PGR revealed that one of them, which we named as circPGR, was required for ER-positive breast cancer cell growth and tumorigenesis. CircPGR was found to be localized in the cytosol of cells and functioned as a competing endogenous RNA (ceRNA) to sponge miR-301a-5p to regulate the expression of multiple cell cycle genes. The clinical relevance of circPGR was underscored by its high and specific expression in ER-positive breast cancer cell lines and clinical breast cancer tissue samples. Accordingly, anti-sense oligonucleotide (ASO) targeting circPGR was proven to be effective in suppressing ER-positive breast cancer cell growth. These findings reveled that, besides the well-known messenger RNA (mRNA), microRNA (miRNA), long non-coding RNA (lncRNA) and enhancer RNA (eRNA) programs, estrogen also induced a circRNA program, and exemplified by circPGR, these estrogen-induced circRNAs were required for ER-positive breast cancer cell growth, providing a new class of therapeutic targets for ER-positive breast cancer.
雌激素和雌激素受体(ER)调节的基因转录事件已被广泛认为参与了 ER 阳性乳腺癌的发生。同时,环状 RNA(circRNA)作为一类新的功能性非编码 RNA(ncRNA),在多种病理过程中具有重要作用,如癌症。然而,雌激素调节的 circRNA 程序及其功能仍未被阐明。通过环状 RNA 测序(circRNA-seq)鉴定了雌激素诱导的 circRNA,并进行细胞增殖、集落形成、划痕愈合、Transwell 和肿瘤异种移植实验,以研究雌激素诱导的 circRNA circPGR 的功能。进行 RNA 测序(RNA-seq)和 ceRNA 网络分析,以鉴定 circPGR 的靶基因和与 circPGR 结合的微小 RNA(miRNA)。反义寡核苷酸(ASO)用于评估 circPGR 对 ER 阳性乳腺癌细胞生长的影响。通过环状 RNA 测序(circRNA-seq)进行全基因组环状 RNA 谱分析显示,大量环状 RNA 被雌激素诱导,进一步对源自 PGR 的几个环状 RNA 的功能筛选表明,其中一个我们命名为 circPGR,是 ER 阳性乳腺癌细胞生长和肿瘤发生所必需的。circPGR 被发现位于细胞的细胞质中,并作为竞争性内源性 RNA(ceRNA)发挥作用,以海绵 miR-301a-5p 来调节多个细胞周期基因的表达。circPGR 在 ER 阳性乳腺癌细胞系和临床乳腺癌组织样本中的高特异性表达突出了其临床相关性。相应地,针对 circPGR 的反义寡核苷酸(ASO)被证明在抑制 ER 阳性乳腺癌细胞生长方面是有效的。这些发现表明,除了众所周知的信使 RNA(mRNA)、微小 RNA(miRNA)、长非编码 RNA(lncRNA)和增强子 RNA(eRNA)程序外,雌激素还诱导了环状 RNA 程序,以 circPGR 为例,这些雌激素诱导的 circRNA 是 ER 阳性乳腺癌细胞生长所必需的,为 ER 阳性乳腺癌提供了一类新的治疗靶点。